keyword
MENU ▼
Read by QxMD icon Read
search

ingenol mebutate

keyword
https://www.readbyqxmd.com/read/28895376/erosive-pustular-dermatosis-of-the-scalp-induced-by-ingenol-mebutate
#1
Lucia Brambilla, Athanasia Tourlaki, Gianluca Nazzaro
No abstract text is available yet for this article.
September 8, 2017: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/28859143/the-effect-of-wool-hydrolysates-on-squamous-cell-carcinoma-cells-in-vitro-possible-implications-for-cancer-treatment
#2
Tatsiana Damps, Anna Katarzyna Laskowska, Tomasz Kowalkowski, Monika Prokopowicz, Anna Katarzyna Puszko, Piotr Sosnowski, Joanna Czuwara, Marek Konop, Krzysztof Różycki, Joanna Karolina Borkowska, Aleksandra Misicka, Lidia Rudnicka
Squamous cell carcinoma of the skin is the second most common cutaneous malignancy. Despite various available treatment methods and advances in noninvasive diagnostic techniques, the incidence of metastatic cutaneous squamous cell carcinoma is rising. Deficiency in effective preventive or treatment methods of transformed keratinocytes leads to necessity of searching for new anticancer agents. The present study aims to evaluate the possibility of using wool hydrolysates as such agents. Commercially available compounds such as 5-fluorouracil, ingenol mebutate, diclofenac sodium salt were also used in this study...
2017: PloS One
https://www.readbyqxmd.com/read/28858927/clinical-and-histologic-evaluation-of-ingenol-mebutate-0-015-gel-for-the-cosmetic-improvement-of-photoaged-skin
#3
Marc Z Handler, Bradley S Bloom, David J Goldberg
BACKGROUND: No studies have examined the use of topical ingenol mebutate for improvement of photoaged skin. OBJECTIVE: To evaluate clinical results of ingenol mebutate gel applied to photoaged skin and to quantify improvement at 7, 30, and 60 days after application. MATERIALS AND METHODS: Twenty-five subjects were enrolled in the study. Picato (ingenol mebutate) (LEO Pharma, Parsippany, NJ) gel was applied to an area with a known actinic keratosis daily for 3 days...
August 30, 2017: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/28761314/a-case-of-bowen-s-disease-successfully-treated-with-ingenol-mebutate-gel
#4
Je-Byeong Chae, Jung-Tae Park, Bo-Ri Kim, Chang-Hun Huh, Kyoung-Chan Park, Jung-Won Shin
No abstract text is available yet for this article.
August 2017: Annals of Dermatology
https://www.readbyqxmd.com/read/28685901/erosive-pustular-dermatosis-of-the-scalp-following-topical-ingenol-mebutate-for-actinic-keratoses
#5
Mario Vaccaro, Francesco Borgia, Lorenzo Gasco, Serafinella P Cannavò
No abstract text is available yet for this article.
July 7, 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/28661992/treatment-patterns-outcomes-and-patient-satisfaction-of-primary-epidermally-limited-nonmelanoma-skin-cancer
#6
Benjamin A Drew, Pritesh S Karia, Ariana N Mora, Christine A Liang, Chrysalyne D Schmults
BACKGROUND: Epidermally limited nonmelanoma skin cancer (ELNMSC) (superficial basal cell carcinoma [SBCC] and squamous cell carcinoma in situ [SCCIS]) is common. Data on outcomes and patient satisfaction are lacking. OBJECTIVE: To examine treatment efficacy and satisfaction in ELNMSC patients. PATIENTS AND METHODS: Retrospective cohort study of adults with primary SBCC or SCCIS. A 25% random subset completed a satisfaction questionnaire. RESULTS: Five hundred and fifty patients with 227 SBCC and 451 SCCIS were included; 329 tumors (49%) were treated with Mohs micrographic surgery (MMS) and 349 (51%) with non-MMS (imiquimod [n = 26], 5% 5-fluorouracil [n = 234], ingenol mebutate [n = 32], or cryotherapy [n = 57])...
June 28, 2017: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/28658998/patient-reported-outcomes-in-topical-field-treatment-of-actinic-keratosis-in-swedish-and-danish-patients
#7
Hanna Norrlid, Jenny M Norlin, Heidi Holmstrup, Irena Malmberg, Karin Sartorius, Henrik Thormann, Gregor B E Jemec, Gunnel Ragnarson Tennvall
Topical treatments in dermatology can be long, complex and lead to nonadherence and nonpersistence to prescribed treatment. Clinical efficacy observed in randomized clinical trials (RCT) may therefore be reduced in real-world clinical practice. The objective of this study was to analyze patient-reported treatment adherence, treatment satisfaction and health-related quality of life (HRQoL) with topical treatments of actinic keratosis (AK) in routine clinical practice in Denmark and Sweden. Adult patients prescribed field-directed topical AK treatments with diclofenac gel, imiquimod or ingenol mebutate per routine clinical practice were eligible for the observational RAPID-ACT study...
June 29, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28628679/safety-and-efficacy-of-escalating-doses-of-ingenol-mebutate-for-field-treatment-of-actinic-keratosis-on-the-full-face-full-balding-scalp-or-chest
#8
C William Hanke, Brian Berman, Neil Swanson, David M Pariser, Jonathan S Weiss, Michael Bukhalo, Torsten Skov, John Villumsen, Daniel Siegel
<p>Background: Actinic keratosis (AK) can affect large skin areas. Ingenol mebutate (IngMeb) gel (0.015% and 0.05%) is approved for topical treatment of AK in a single contiguous area of ~25 cm2.</p> <p>Objective: The study sought to determine the maximum tolerated dose (MTD), efficacy, and tolerability of IngMeb applied to AK on a contiguous area less than equal to 250 cm2.</p> <p>Methods: Part 1 determined the MTD of IngMeb at 7 concentrations for 2 or 3 days. Part 2 assessed efficacy and tolerability at the MTD and one dose lower for 2 or 3 days vs vehicle...
May 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28628678/assessment-of-efficacy-and-irritation-of-ingenol-mebutate-gel-0-015-used-with-or-without-dimethicone-lotion-for-treatment-of-actinic-keratosis-on-the-face
#9
Shelbi C Jim On, Peter W Hashim, John K Nia, Mark G Lebwohl
<p>Background: Ingenol mebutate gel 0.015% provides high clearance rates for actinic keratosis (AK) on the face and scalp but causes transient local skin responses (LSRs).</p> <p>Objective: This study sought to determine whether the application of 1% dimethicone would decrease ingenol mebutate-associated LSRs and/or affect efficacy during the treatment of multiple AKs on the face.</p> <p>Methods: Ingenol mebutate gel 0.015% was applied for 3 days to two 25 cm2 areas, each containing 3 to 8 AKs on the face of each subject, followed by application of 1% dimethicone lotion in an investigator-blinded manner to one randomly selected AK-containing area until LSRs were no longer present...
May 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28621441/exuberant-granulation-tissue-successfully-treated-with-ingenol-mebutate-two-cases-report
#10
LETTER
María Encarnación Gómez Sánchez, María Luisa Martínez Martínez, Tomás Toledo Pastrana, Almudena Nuño González, Jose Manuel Azaña Defez, Jose Luis Agudo Mena
No abstract text is available yet for this article.
July 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/28619577/ingenol-mebutate-for-the-management-of-genital-warts-in-sensitive-anatomic-locations
#11
Stephan Alexander Braun, Peter Arne Gerber
No abstract text is available yet for this article.
July 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28580871/pharmacoeconomic-evaluations-in-the-treatment-of-actinic-keratoses
#12
Keith Tolley, Giuseppe Argenziano, Pier Giacomo Calzavara-Pinton, Thomas Larsson, Lasse Ryttig
Actinic keratoses (AKs) develop as a consequence of chronic ultraviolet (UV) exposure and exist on a continuum with squamous cell carcinoma (SCC). As one of the most common conditions treated by dermatologists, AK places a significant burden on patients and the healthcare system. A range of treatments are used, including topical treatments that target the visible and subclinical lesions. The goal of such therapies is to achieve complete clearance of AKs and eliminate the risk of progression to SCC. Robust meta-analyses of trial data can provide valuable information for the optimal management of AK and cost-effectiveness evaluations of topical treatments, such as ingenol mebutate gel and diclofenac...
June 2017: International Journal of Immunopathology and Pharmacology
https://www.readbyqxmd.com/read/28579816/tattoo-removal-with-ingenol-mebutate
#13
Sarah-Jane Cozzi, Thuy T Le, Steven M Ogbourne, Cini James, Andreas Suhrbier
An increasing number of people are getting tattoos; however, many regret the decision and seek their removal. Lasers are currently the most commonly used method for tattoo removal; however, treatment can be lengthy, costly, and sometimes ineffective, especially for certain colors. Ingenol mebutate is a licensed topical treatment for actinic keratoses. Here, we demonstrate that two applications of 0.1% ingenol mebutate can efficiently and consistently remove 2-week-old tattoos from SKH/hr hairless mice. Treatment was associated with relocation of tattoo microspheres from the dermis into the posttreatment eschar...
2017: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/28524709/pharmacokinetics-of-ingenol-mebutate-gel-under-maximum-use-conditions-in-large-treatment-areas
#14
Alicia D Bucko, Michael Jarratt, Dowling B Stough, Laerke Kyhl, John Villumsen, Anders Hall
PURPOSE: Actinic keratoses (AKs) exist on a continuum with squamous cell carcinoma and can occur as sub-clinical and clinically visible lesions in cancerized fields on sun-damaged skin. Ingenol mebutate effectively treats AKs on areas up to 25 cm(2), but actinic keratosis can affect larger areas of skin. This trial evaluated systemic exposure and safety of ingenol mebutate gel on larger areas of skin under maximum use conditions. METHODS: Phase I, multicenter, open-label, uncontrolled, non-randomized trial...
May 25, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28449867/cost-effectiveness-of-ingenol-mebutate-gel-for-the-treatment-of-actinic-keratosis-in-greece
#15
Kostas Athanasakis, Nadia Boubouchairopoulou, Filippos Tarantilis, Vasiliki Tsiantou, Stathis Kontodimas, John Kyriopoulos
PURPOSE: The present study aimed to perform a cost-effectiveness analysis of ingenol mebutate (IM) versus other topical alternatives for the treatment of actinic keratosis (AK). METHODS: The analysis used a decision tree to calculate the clinical effects and costs of AK first-line treatments, IM (2-3 days), diclofenac 3% (for 8 or 12 weeks), imiquimod 5% (for 4 or 8 weeks), during a 24-month horizon, using discrete intervals of 6 months. A hypothetical cohort of immunocompetent adult patients with clinically confirmed AK on the face and scalp or trunk and extremities was considered...
May 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28408848/ingenol-mebutate-in-low-amounts-for-the-treatment-of-actinic-keratosis-in-korean-patients
#16
Hyun Jae Joe, Byung Ho Oh
BACKGROUND: Ingenol mebutate (IM), a novel agent for field therapy of actinic keratosis (AK), has a drawback of inducing local skin reactions (LSRs), which may cause discomfort in patients. To reduce the LSRs, we tried the application of IM in low amounts. OBJECTIVE: The purpose of this study was to review Korean patients with AK being treated with IM and evaluate the LSRs and therapeutic outcomes of low amounts of IM. METHODS: We retrospectively reviewed 47 patients with AK on the face...
2017: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/28406719/structured-expert-consensus-on-actinic-keratosis-treatment-algorithm-focusing-on-daylight-pdt
#17
Piergiacomo Calzavara-Pinton, Merete Hædersdal, Kirk Barber, Nicole Basset-Seguin, María Emilia Del Pino Flores, Peter Foley, Gaston Galimberti, Rianne Gerritsen, Yolanda Gilarbete, Sally Ibbotson, Ketty Peris, Sheetal Sapra, Eleni Sotiriou, Luis Torezan, Claas Ulrich, Jonathan Guillemot, Janek Hendrich, Rolf-Markus Szeimies
BACKGROUND: A practical and up-to-date consensus among experts is paramount to further improve patient care in actinic keratosis (AK). OBJECTIVES: To develop a structured consensus statement on the diagnosis, classification, and practical management of AK based on up-to-date information. METHODS: A systematic review of AK clinical guidelines was conducted. This informed the preparation of a 3-round Delphi procedure followed by a consensus meeting, which combined the opinions of 16 clinical experts from 13 countries, to construct a structured consensus statement and a treatment algorithm positioning daylight photodynamic therapy (dl-PDT) among other AK treatment options...
April 1, 2017: Journal of Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/28398427/disseminated-superficial-actinic-porokeratosis-treated-with-ingenol-mebutate-gel-0-05
#18
Isabella Anderson, Ethan T Routt, Shelbi C Jim On
Disseminated superficial actinic porokeratosis (DSAP) is a chronic condition characterized by numerous atrophic papules and patches with a distinctive peripheral keratotic ridge, typically found on sun-exposed areas. Treatment of DSAP is warranted not only for cosmetic and symptomatic benefits but also to prevent malignant transformation. Successful treatment of DSAP often is difficult and frequently requires the use of multiple modalities. Ingenol mebutate gel 0.05% is a topical medication primarily used for the treatment of actinic keratosis (AK) by inducing cell death...
March 2017: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/28370377/analysis-of-apoptosis-associated-molecules-erythroid-differentiation-regulator-1-bcl-2-and-p53-in-actinic-keratosis-after-treatment-with-ingenol-mebutate
#19
Yu Ri Woo, Ji Hong Lim, Seo-Won Jeong, Dae Ho Cho, Hyun Jeong Park
AK is the most common cutaneous premalignant neoplasm precursor of malignant skin tumors. The aberrant apoptotic pathway is thought to be associated with pathogenesis of AK. Ingenol mebutate has been shown to be effective and safe for treatment of AK. However, the effect of ingenol mebutate on apoptosis-related molecules using human skin samples has not been studied well. Erythroid differentiation regulator 1 (Erdr1) was recently reported to play a crucial role in malignant skin cancers like malignant melanoma...
March 31, 2017: Experimental Dermatology
https://www.readbyqxmd.com/read/28367259/united-states-food-and-drug-administration-product-label-changes
#20
Leon Kircik, Julie C Sung, Linda Stein-Gold, Gary Goldenberg
Once a drug has been approved by the United States Food and Drug Administration and is on the market, the Food and Drug Administration communicates new safety information through product label changes. Most of these label changes occur after a spontaneous report to either the drug manufacturing companies or the Food and Drug Administration MedWatch program. As a result, 400 to 500 label changes occur every year. Actinic keratosis treatments exemplify the commonality of label changes throughout the postmarket course of a drug...
February 2017: Journal of Clinical and Aesthetic Dermatology
keyword
keyword
51369
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"